The use of back propagation neural networks and 18F-Florbetapir PET for early detection of Alzheimer's disease using Alzheimer's Disease Neuroimaging Initiative database

A systematic literature review on the significance of deep learning and machine learning in predicting Alzheimer's disease

BACKGROUND

Alzheimer's disease (AD) is the most prevalent cause of dementia, characterized by a steady decline in mental, behavioral, and social abilities and impairs a person's capacity for independent functioning. It is a fatal neurodegenerative disease primarily affecting older adults.

OBJECTIVES

The purpose of this literature review is to investigate various AD detection techniques, datasets, input modalities, algorithms, libraries, and performance evaluation metrics used to determine which model or strategy may provide superior performance.

METHOD

The initial search yielded 807 papers, but only 100 research articles were chosen after applying the inclusion-exclusion criteria. This SLR analyzed research items published between January 2019 and December 2022. The ACM, Elsevier, IEEE Xplore Digital Library, PubMed, Springer and Taylor & Francis were systematically searched. The current study considers articles that used Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), APOe4 genotype, Diffusion Tensor Imaging (DTI) and Cerebrospinal Fluid (CSF) biomarkers. The study was performed following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

CONCLUSION

According to the literature survey, most studies (n = 76) used the DL strategy. The datasets used by studies were primarily derived from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The majority of studies (n = 73) used single-modality neuroimaging data, while the remaining used multi-modal input data. In a multi-modality approach, the combination of MRI and PET scans is commonly preferred. Also, Regarding the algorithm used, Convolution Neural Network (CNN) showed the highest accuracy, 100 %, in classifying AD vs. CN subjects whereas the SVM was the most common ML algorithm, with a maximum accuracy of 99.82 %.

Optimized Convolutional Fusion for Multimodal Neuroimaging in Alzheimer's Disease Diagnosis: Enhancing Data Integration and Feature Extraction

Multimodal neuroimaging has gained traction in Alzheimer's Disease (AD) diagnosis by integrating information from multiple imaging modalities to enhance classification accuracy. However, effectively handling heterogeneous data sources and overcoming the challenges posed by multiscale transform methods remains a significant hurdle. This article proposes a novel approach to address these challenges. To harness the power of diverse neuroimaging data, we employ a strategy that leverages optimized convolution techniques. These optimizations include varying kernel sizes and the incorporation of instance normalization, both of which play crucial roles in feature extraction from magnetic resonance imaging (MRI) and positron emission tomography (PET) images. Specifically, varying kernel sizes allow us to adapt the receptive field to different image characteristics, enhancing the model's ability to capture relevant information. Furthermore, we employ transposed convolution, which increases spatial resolution of feature maps, and it is optimized with varying kernel sizes and instance normalization. This heightened resolution facilitates the alignment and integration of data from disparate MRI and PET data. The use of larger kernels and strides in transposed convolution expands the receptive field, enabling the model to capture essential cross-modal relationships. Instance normalization, applied to each modality during the fusion process, mitigates potential biases stemming from differences in intensity, contrast, or scale between modalities. This enhancement contributes to improved model performance by reducing complexity and ensuring robust fusion. The performance of the proposed fusion method is assessed on three distinct neuroimaging datasets, which include: Alzheimer's Disease Neuroimaging Initiative (ADNI), consisting of 50 participants each at various stages of AD for both MRI and PET (Cognitive Normal, AD, and Early Mild Cognitive); Open Access Series of Imaging Studies (OASIS), consisting of 50 participants each at various stages of AD for both MRI and PET (Cognitive Normal, Mild Dementia, Very Mild Dementia); and whole-brain atlas neuroimaging (AANLIB) (consisting of 50 participants each at various stages of AD for both MRI and PET (Cognitive Normal, AD). To evaluate the quality of the fused images generated via our method, we employ a comprehensive set of evaluation metrics, including Structural Similarity Index Measurement (SSIM), which assesses the structural similarity between two images; Peak Signal-to-Noise Ratio (PSNR), which measures how closely the generated image resembles the ground truth; Entropy (E), which assesses the amount of information preserved or lost during fusion; the Feature Similarity Indexing Method (FSIM), which assesses the structural and feature similarities between two images; and Edge-Based Similarity (EBS), which measures the similarity of edges between the fused and ground truth images. The obtained fused image is further evaluated using a Mobile Vision Transformer. In the classification of AD vs. Cognitive Normal, the model achieved an accuracy of 99.00%, specificity of 99.00%, and sensitivity of 98.44% on the AANLIB dataset.

Multimodal cross enhanced fusion network for diagnosis of Alzheimer's disease and subjective memory complaints

Deep learning methods using multimodal imagings have been proposed for the diagnosis of Alzheimer's disease (AD) and its early stages (SMC, subjective memory complaints), which may help to slow the progression of the disease through early intervention. However, current fusion methods for multimodal imagings are generally coarse and may lead to suboptimal results through the use of shared extractors or simple downscaling stitching. Another issue with diagnosing brain diseases is that they often affect multiple areas of the brain, making it important to consider potential connections throughout the brain. However, traditional convolutional neural networks (CNNs) may struggle with this issue due to their limited local receptive fields. To address this, many researchers have turned to transformer networks, which can provide global information about the brain but can be computationally intensive and perform poorly on small datasets. In this work, we propose a novel lightweight network called MENet that adaptively recalibrates the multiscale long-range receptive field to localize discriminative brain regions in a computationally efficient manner. Based on this, the network extracts the intensity and location responses between structural magnetic resonance imagings (sMRI) and 18-Fluoro-Deoxy-Glucose Positron Emission computed Tomography (FDG-PET) as an enhancement fusion for AD and SMC diagnosis. Our method is evaluated on the publicly available ADNI datasets and achieves 97.67% accuracy in AD diagnosis tasks and 81.63% accuracy in SMC diagnosis tasks using sMRI and FDG-PET. These results achieve state-of-the-art (SOTA) performance in both tasks. To the best of our knowledge, this is one of the first deep learning research methods for SMC diagnosis with FDG-PET.

Efficient Training on Alzheimer's Disease Diagnosis with Learnable Weighted Pooling for 3D PET Brain Image Classification

Three-dimensional convolutional neural networks (3D CNNs) have been widely applied to analyze Alzheimer's disease (AD) brain images for a better understanding of the disease progress or predicting the conversion from cognitively impaired (CU) or mild cognitive impairment status. It is well-known that training 3D-CNN is computationally expensive and with the potential of overfitting due to the small sample size available in the medical imaging field. Here we proposed a novel 3D-2D approach by converting a 3D brain image to a 2D fused image using a Learnable Weighted Pooling (LWP) method to improve efficient training and maintain comparable model performance. By the 3D-to-2D conversion, the proposed model can easily forward the fused 2D image through a pre-trained 2D model while achieving better performance over different 3D and 2D baselines. In the implementation, we chose to use ResNet34 for feature extraction as it outperformed other 2D CNN backbones. We further showed that the weights of the slices are location-dependent and the model performance relies on the 3D-to-2D fusion view, with the best outcomes from the coronal view. With the new approach, we were able to reduce 75% of the training time and increase the accuracy to 0.88, compared with conventional 3D CNNs, for classifying amyloid-beta PET imaging from the AD patients from the CU participants using the publicly available Alzheimer's Disease Neuroimaging Initiative dataset. The novel 3D-2D model may have profound implications for timely AD diagnosis in clinical settings in the future.

Alzheimer's Disease: A Silent Pandemic - A Systematic Review on the Situation and Patent Landscape of the Diagnosis

BACKGROUND

Alzheimer's disease (AD) is characterized by cognitive impairment, tau protein deposits, and amyloid beta plaques. AD impacted 44 million people in 2016, and it is estimated to affect 100 million people by 2050. AD is disregarded as a pandemic compared with other diseases. To date, there is no effective treatment or diagnosis.

OBJECTIVE

We aimed to discuss the current tools used to diagnose COVID-19, to point out their potential to be adapted for AD diagnosis, and to review the landscape of existing patents in the AD field and future perspectives for AD diagnosis.

METHOD

We carried out a scientific screening following a research strategy in PubMed; Web of Science; the Derwent Innovation Index; the KCI-Korean Journal Database; SciELO; the Russian Science Citation index; and the CDerwent, EDerwent, and MDerwent index databases.

RESULTS

A total of 326 from 6,446 articles about AD and 376 from 4,595 articles about COVID-19 were analyzed. Of these, AD patents were focused on biomarkers and neuroimaging with no accurate, validated diagnostic methods, and only 7% of kit development patents were found. In comparison, COVID-19 patents were 60% about kit development for diagnosis; they are highly accurate and are now commercialized.

CONCLUSION

AD is still neglected and not recognized as a pandemic that affects the people and economies of all nations. There is a gap in the development of AD diagnostic tools that could be filled if the interest and effort that has been invested to tackle the COVID-19 emergency could also be applied for innovation.

Hybrid Machine Learning Model for Body Fat Percentage Prediction Based on Support Vector Regression and Emotional Artificial Neural Networks

Obesity or excessive body fat causes multiple health problems and diseases. However, obesity treatment and control need an accurate determination of body fat percentage (BFP). The existing methods for BFP estimation require several procedures, which reduces their cost-effectivity and generalization. Therefore, developing cost-effective models for BFP estimation is vital for obesity treatment. Machine learning models, particularly hybrid models, have a strong ability to analyze challenging data and perform predictions by combining different characteristics of the models. This study proposed a hybrid machine learning model based on support vector regression and emotional artificial neural networks (SVR-EANNs) for accurate recent BFP prediction using a primary BFP dataset. SVR was applied as a consistent attribute selection model on seven properties and measurements, using the left-out sensitivity analysis, and the regression ability of the EANN was considered in the prediction phase. The proposed model was compared to seven benchmark machine learning models. The obtained results show that the proposed hybrid model (SVR-EANN) outperformed other machine learning models by achieving superior results in the three considered evaluation metrics. Furthermore, the proposed model suggested that abdominal circumference is a significant factor in BFP prediction, while age has a minor effect.

Single and Combined Neuroimaging Techniques for Alzheimer's Disease Detection

Alzheimer's disease (AD) consists of the gradual process of decreasing volume and quality of neuron connection in the brain, which consists of gradual synaptic integrity and loss of cognitive functions. In recent years, there has been significant attention in AD classification and early detection with machine learning algorithms. There are different neuroimaging techniques for capturing data and using it for the classification task. Input data as images will help machine learning models to detect different biomarkers for AD classification. This marker has a more critical role for AD detection than other diseases because beta-amyloid can extract complex structures with some metal ions. Most researchers have focused on using 3D and 4D convolutional neural networks for AD classification due to reasonable amounts of data. Also, combination neuroimaging techniques like functional magnetic resonance imaging and positron emission tomography for AD detection have recently gathered much attention. However, gathering a combination of data can be expensive, complex, and tedious. For time consumption reasons, most patients prefer to throw one of the neuroimaging techniques. So, in this review article, we have surveyed different research studies with various neuroimaging techniques and ML methods to see the effect of using combined data as input. The result has shown that the use of the combination method would increase the accuracy of AD detection. Also, according to the sensitivity metrics from different machine learning methods, MRI and fMRI showed promising results.

Ensemble of ROI-based convolutional neural network classifiers for staging the Alzheimer disease spectrum from magnetic resonance imaging

Patches from three orthogonal views of selected cerebral regions can be utilized to learn convolutional neural network (CNN) models for staging the Alzheimer disease (AD) spectrum including preclinical AD, mild cognitive impairment due to AD, and dementia due to AD and normal controls. Hippocampi, amygdalae and insulae were selected from the volumetric analysis of structured magnetic resonance images (MRIs). Three-view patches (TVPs) from these regions were fed to the CNN for training. MRIs were classified with the SoftMax-normalized scores of individual model predictions on TVPs. The significance of each region of interest (ROI) for staging the AD spectrum was evaluated and reported. The results of the ensemble classifier are compared with state-of-the-art methods using the same evaluation metrics. Patch-based ROI ensembles provide comparable diagnostic performance for AD staging. In this work, TVP-based ROI analysis using a CNN provides informative landmarks in cerebral MRIs and may have significance in clinical studies and computer-aided diagnosis system design.

Detection of COVID-19 from Chest X-Ray Images Using Convolutional Neural Networks

The detection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), which is responsible for coronavirus disease 2019 (COVID-19), using chest X-ray images has life-saving importance for both patients and doctors. In addition, in countries that are unable to purchase laboratory kits for testing, this becomes even more vital. In this study, we aimed to present the use of deep learning for the high-accuracy detection of COVID-19 using chest X-ray images. Publicly available X-ray images (1583 healthy, 4292 pneumonia, and 225 confirmed COVID-19) were used in the experiments, which involved the training of deep learning and machine learning classifiers. Thirty-eight experiments were performed using convolutional neural networks, 10 experiments were performed using five machine learning models, and 14 experiments were performed using the state-of-the-art pre-trained networks for transfer learning. Images and statistical data were considered separately in the experiments to evaluate the performances of models, and eightfold cross-validation was used. A mean sensitivity of 93.84%, mean specificity of 99.18%, mean accuracy of 98.50%, and mean receiver operating characteristics–area under the curve scores of 96.51% are achieved. A convolutional neural network without pre-processing and with minimized layers is capable of detecting COVID-19 in a limited number of, and in imbalanced, chest X-ray images.

Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives

Artificial intelligence and machine learning based approaches are increasingly finding their way into various areas of nuclear medicine imaging. With the technical development of new methods and the expansion to new fields of application, this trend is likely to become even more pronounced in future. Possible means of application range from automated image reading and classification to correlation with clinical outcomes and to technological applications in image processing and reconstruction. In the context of tumor imaging, that is, predominantly FDG or PSMA PET imaging but also bone scintigraphy, artificial intelligence approaches can be used to quantify the whole-body tumor volume, for the segmentation and classification of pathological foci or to facilitate the diagnosis of micro-metastases. More advanced applications aim at the correlation of image features that are derived by artificial intelligence with clinical endpoints, for example, whole-body tumor volume with overall survival. In nuclear medicine imaging of benign diseases, artificial intelligence methods are predominantly used for automated and/or facilitated image classification and clinical decision making. Automated feature selection, segmentation and classification of myocardial perfusion scintigraphy can help in identifying patients that would benefit from intervention and to forecast clinical prognosis. Automated reporting of neurodegenerative diseases such as Alzheimer's disease might be extended to early diagnosis-being of special interest, if targeted treatment options might become available. Technological approaches include artificial intelligence-based attenuation correction of PET images, image reconstruction or anatomical landmarking. Attenuation correction is of special interest for avoiding the need of a coregistered CT scan, in the process of image reconstruction artefacts might be reduced, or ultra low-dose PET images might be denoised. The development of accurate ultra low-dose PET imaging might broaden the method's applicability, for example, toward oncologic PET screening. Most artificial intelligence approaches in nuclear medicine imaging are still in early stages of development, further improvements are necessary for broad clinical applications. In this review, we describe the current trends in the context fields of body oncology, cardiac imaging, and neuroimaging while an additional section puts emphasis on technological trends. Our aim is not only to describe currently available methods, but also to place a special focus on the description of possible future developments.